Affiliation:
1. Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy/Collaborative Innovation Center for Biotherapy, West China Hospital Sichuan University Chengdu China
2. Department of Head and Neck Oncology, West China Hospital Sichuan University Chengdu China
3. Precision Medicine Key Laboratory of Sichuan Province & Precision Medicine Research Center, West China Hospital Sichuan University Chengdu China
4. Research Unit of Gene and Immunotherapy Chinese Academy of Medical Sciences Chengdu China
Abstract
AbstractCD25, also known as the interleukin‐2 receptor α chain (IL‐2Rα), is highly expressed on regulatory T cells (Tregs), but relatively lower on effector T cells (Teffs). This makes it a potential target for Treg depletion, which can be used in tumor immunotherapy. However, marketed anti‐CD25 antibodies (Basiliximab and Daclizumab) were originally developed as immunosuppressive drugs to prevent graft rejection, because these antibodies can block IL‐2 binding to CD25 on Teffs, which in turn destroys the function of Teffs. Recent studies have shown that non‐IL‐2‐blocking anti‐CD25 antibodies have displayed exciting antitumor effects. Here, we screened out a non‐IL‐2‐blocking anti‐CD25 monoclonal antibody (mAb) 7B7 by hybridoma technology, and confirmed its antitumor activity via depleting Tregs in a CD25 humanized mouse model. Subsequently, we verified that the humanized 7B7, named as h7B7‐15S, has comparable activities to 7B7, and that its Treg depletion is further increased when combined with anti‐CTLA‐4, leading to enhanced remodeling of the tumor immune microenvironment. Moreover, our findings reveal that the Fab form of h7B7‐15S has the ability to deplete Tregs, independent of the Fc region. Taken together, our studies expand the application of anti‐CD25 in tumor immunotherapy and provide insight into the underlying mechanism.